Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study

Icotinib versus docetaxel used in lung adenocarcinoma patients who failed platinum-based chemotherapy: a retrospective study

Wei He, Yan Zhang, Yu Xiong, Feng-juan Dai, Qing-xia Fan The Department of Oncology, The First Affiliated Hospital of Zhengzhou University, Zhengzhou, People’s Republic of China Background: The efficacy and safety of epidermal growth factor receptor tyrosine kinase inhibitors have been s...

Full description

Bibliographic Details
Main Authors:	He W, Zhang Y, Xiong Y, Dai FJ, Fan QX
Format:	Article
Language:	English
Published:	Dove Medical Press 2016-07-01
Series:	OncoTargets and Therapy
Subjects:	icotinib docetaxel second-line therapy lung adenocarcinoma EGFR-TKIs
Online Access:	https://www.dovepress.com/icotinib-versus-docetaxel-used-in-lung-adenocarcinoma-patients-who-fai-peer-reviewed-article-OTT

Similar Items

Efficacy of icotinib in advanced lung squamous cell carcinoma
by: Shuai Liang, et al.
Published: (2018-09-01)

Effects of Docetaxel Combined with Icotinib on Serum Tumor Markers and Quality of Life of Patients with Advanced Non-Small Cell Lung Cancer
by: Huawei LIN, et al.
Published: (2020-10-01)

Efficacy and safety of icotinib in patients with brain metastases from lung adenocarcinoma
by: Xu J, et al.
Published: (2016-05-01)

Effective treatment with icotinib in lung adenocarcinoma with EGFR and ALK co-alterations and brain metastasis
by: Ye CY, et al.
Published: (2016-10-01)

Clinical Observation of Icotinib Hydrochloride in First-line Therapy  for Pulmonary Adenocarcinoma
by: Xinjie YANG, et al.
Published: (2013-07-01)

Adenocarcinoma of High-Grade Patterns Associated with Distinct Outcome of First-Line Chemotherapy or EGFR-TKIs in Patients of Relapsed Lung Cancer
by: Yu X, et al.
Published: (2021-05-01)

Efficacy of Icotinib for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Yiping ZHANG, et al.
Published: (2013-03-01)

Clinical Analysis of Icotinib on Beneficiary of  Advanced Non-small Cell Lung Cancer with EGFR Common Mutation
by: Xiaowen JIANG, et al.
Published: (2016-04-01)

Icotinib versus Cisplatin Plus Docetaxel as Adjuvant Chemotherapy in Patients with Stage II (N1+) Non-Small Cell Lung Cancer Harboring Positive EGFR Mutations: A Single-Center Retrospective Study
by: Pan S, et al.
Published: (2021-02-01)

Icotinib hydrochloride enhances chemo- and radiosensitivity by inhibiting EGFR signaling and attenuating RAD51 expression and function in Hela S3 cells
by: Wang X, et al.
Published: (2018-03-01)

The Combination of Icotinib Hydrochloride and Fluzoparib Enhances the Radiosensitivity of Biliary Tract Cancer Cells
by: Zhu L, et al.
Published: (2020-11-01)

Real‐world efficacy and potential mechanism of resistance of icotinib in Asian advanced non‐small cell lung cancer with EGFR uncommon mutations: A multi‐center study
by: Lei Lei, et al.
Published: (2020-01-01)

Positive response to Icotinib in metastatic lung adenocarcinoma with acquiring EGFR Leu792H mutation after AZD9291 treatment: a case report
by: Junhui Wang, et al.
Published: (2019-02-01)

Sequence-dependent synergistic cytotoxicity of icotinib and pemetrexed in human lung cancer cell lines in vitro and in vivo
by: Tianze Liu, et al.
Published: (2019-04-01)

Clinical Observation of Icotinib Hydrochloride for Advanced Non-small Cell Lung Cancer Patients with EGFR Status Identified
by: Xi LI, et al.
Published: (2015-12-01)

Re-biopsy status among Chinese non-small-cell lung cancer patients who progressed after icotinib therapy
by: Wang H, et al.
Published: (2018-10-01)

Nrf2 and Keap1 Abnormalities in 104 Lung Adenocarcinoma Cases and Association with Clinicopathologic Features
by: Yu XIAO, et al.
Published: (2018-03-01)

Efficacy and safety of icotinib as first-line therapy in patients with advanced non-small-cell lung cancer
by: Shen YW, et al.
Published: (2016-02-01)

Bilirubin Can Be Used as a Prognostic Factor for Lung Adenocarcinoma Patients with EGFR Mutations
by: Geng Y, et al.
Published: (2020-10-01)

Combination therapy of brain radiotherapy and EGFR-TKIs is more effective than TKIs alone for EGFR-mutant lung adenocarcinoma patients with asymptomatic brain metastasis
by: Yanxin Chen, et al.
Published: (2019-08-01)

Metastatic Prostatic Ductal Adenocarcinoma Successfully Treated with Docetaxel Chemotherapy: A Case Report
by: Ryo Fujiwara, et al.
Published: (2015-08-01)

Comparison of the Efficacy and Safety of Icotinib with Standard Second-line  Chemotherapy in Previously Treated Advanced Non-small Cell Lung Cancer
by: Shuyang YAO, et al.
Published: (2015-06-01)

Cumulative smoking dose affects the clinical outcomes of EGFR-mutated lung adenocarcinoma patients treated with EGFR-TKIs: a retrospective study
by: In Ae Kim, et al.
Published: (2018-07-01)

The Prognostic Value of Baseline Distant Metastasis in Icotinib-Treated Patients with EGFR-Mutated Stage IV Non-Small Cell Lung Cancer
by: Wang L, et al.
Published: (2021-03-01)

Larger tumors are associated with inferior progression‐free survival of first‐line EGFR‐tyrosine kinase inhibitors and a lower abundance of EGFR mutation in patients with advanced non‐small cell lung cancer
by: Yingying Pan, et al.
Published: (2019-04-01)

Benefit from Adjuvant TKIs Versus TKIs Plus Chemotherapy in <i>EGFR</i>-Mutant Stage III-pN2 Lung Adenocarcinoma
by: Qiwen Li, et al.
Published: (2021-04-01)

Icotinib as Adjuvant Treatment for Stage II-IIIA Lung Adenocarcinoma Patients with EGFR Mutation (ICWIP Study): Study Protocol for a Randomised Controlled Trial
by: Liu YT, et al.
Published: (2020-06-01)

Clinical Effects for Patients with Recurrent Advanced Non-small Cell Lung Cancer Treated with Icotinib Hydrochloride
by: Jingying NONG, et al.
Published: (2013-05-01)

Elevated serum CEA levels are associated with the explosive progression of lung adenocarcinoma harboring EGFR mutations
by: Yuan Gao, et al.
Published: (2017-07-01)

Durable Response to Osimertinib in a Chinese Patient with Metastatic Lung Adenocarcinoma Harboring a Rare EGFR L858R/D761Y Compound Mutation
by: Zhu Y, et al.
Published: (2020-10-01)

Vandetanib Treatment in Refractory Advanced Lung Adenocarcinoma Patients:  Five Cases and Review of Literature
by: Lili GUO, et al.
Published: (2012-02-01)

Primary Tumor Resection Improves Survival for EGFR-TKI-Treated Patients With Occult M1a Lung Adenocarcinoma
by: Fangqiu Fu, et al.
Published: (2021-04-01)

KIF5B-EGFR Fusion: A Novel EGFR Mutation in Lung Adenocarcinoma
by: Xu H, et al.
Published: (2020-08-01)

LncRNA APCDD1L-AS1 induces icotinib resistance by inhibition of EGFR autophagic degradation via the miR-1322/miR-1972/miR-324-3p-SIRT5 axis in lung adenocarcinoma
by: Jie Wu, et al.
Published: (2021-01-01)

Association Of Initial Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors Treatment And EGFR Exon 19 Deletion With Frequency Of The T790M Mutation In Non-Small Cell Lung Cancer Patients After Resistance To First-Line Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors
by: Gao W, et al.
Published: (2019-11-01)

Treatment of Advanced NSCLC with Unknown EGFR Gene Status __ TKI or Chemotherapy?
by: Xiaoqing LIU, et al.
Published: (2014-10-01)

Apatinib plus icotinib in treating advanced non-small cell lung cancer after icotinib treatment failure: a retrospective study
by: Xu J, et al.
Published: (2017-10-01)

Role of the Expression Level of Nrf2 in Predicting Response of EGFR-TKIs  in Lung Adenocarcinoma Patients with EGFR Gene Mutations
by: Xiang ZHU, et al.
Published: (2014-02-01)

Icotinib-resistant HCC827 cells produce exosomes with mRNA MET oncogenes and mediate the migration and invasion of NSCLC
by: Yiming Yu, et al.
Published: (2019-10-01)

Icotinib alone or with bevacizumab as first‐line therapy in Chinese patients with advanced nonsquamous non‐small cell lung cancer and activating EGFR mutations: A retrospective study
by: Zhansheng Jiang, et al.
Published: (2021-09-01)